Compass Therapeutics, Inc.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

Q: Sep 30 2021

Regulation FD Disclosure

Results of Operations and Financial Condition

Regulation FD Disclosure

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Regulation FD Disclosure

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Regulation FD Disclosure

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

2.02,9.01

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

No description available

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Notice of Effectiveness

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Registration of Securities on Exchange

Prospectus Supplement for Primary Offering

Certification of approval for listing and registration on a national securities exchange

Notice of Effectiveness

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Definitive Proxy Statement

Lerner Neil

Lerner Neil

Vivo Opportunity Fund Holdings, L.P.

STATE STREET CORP

BIOTECHNOLOGY VALUE FUND L P

Lerner Neil

Anderman Jonathan

Anderman Jonathan

Lerner Neil

Blackstone Holdings II L.P.

Schuetz Thomas J.

BlackRock, Inc.

Schuetz Thomas J.

Sirard Cynthia

Prasad Arjun

GRAY MARY ANN

Boylan James P

GORDON CARL L

Ferneau Philip

Anderman Jonathan

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Draft registration statement (confidential submission)

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC